Company* |
Company* |
Product |
Terms/ |
| | |||
Aclara BioSciences Inc. (ACLA) |
Cell Signaling Technology Inc.* |
CST reagents in conjunction with Aclara's eTag Assay System |
Companies signed a supply and license agreement under which Aclara can use and resell the reagents (12/4) |
|
|||
Avid Bioservices Inc. (subsidiary of Peregrine Pharmaceuticals Inc.; PPHM) |
Undisclosed company |
Agreement for manufacturing a recombinant protein for use in upcoming clinical trials |
Avid also will provide regulatory support; terms and details were not disclosed (11/24) |
|
|||
Avid Bioservices Inc. (subsidiary of Peregrine Pharmaceuticals Inc.; PPHM) |
Medipharm Biotech Co. Ltd.* (China) |
Agreement for manufacturing of Medipharm's tumor necrosis therapy antibody |
Avid will provide process development and manufacturing services to support launch of radiolabeled product in China (11/18) |
|
|||
Avid Bioservices Inc. (subsidiary of Peregrine Pharmaceuticals Inc.; PPHM) |
Undisclosed company |
Agreement to manufacture monoclonal antibodies for upcoming clinical trials |
Avid also will provide the undisclosed firm regulatory support for submission of an IND for clinical trials (10/29) |
|
|||
Barrier Therapeutics Inc.* |
Alliance Pharmaceuticals Ltd.* (UK) and Neopharm Ltd.* (Israel) |
Marketing, sales and distribution agreements for Barrier's initial products |
Alliance would sell products in the UK and Scandinavia, and Neopharm would sell in Israel and Turkey; initial efforts focus on Zimycan, a product being developed for Candida-associated diaper dermititis (12/9) |
|
|||
Biobase GmbH* (Germany) |
Molecular Connections* (India) |
Molecular Connections' NetPro protein-interaction database |
Biobase will distribute NetPro on a worldwide, nonexclusive basis (12/5) |
|
|||
BioVest International Inc.* |
BioE Inc.* |
Supply agreement on antibodies for BioE's stem cell isolation system |
BioE will provide cell lines, which BioVest will optimize for growth and antibody production; terms were not disclosed (10/28) |
|
|||
Cangene Corp. (Canada; TSE:CNJ) |
BioGeneriX AG* (Germany) |
Cangene's recombinant human growth hormone |
BioGeneriX will be the sole distributor of the product in Europe; terms were not disclosed (10/29) |
|
|||
Cambrex Corp. (NYSE:CBM) |
Ortec International Inc. (OTC BB:ORTN) |
Ortec's tissue-engineered product, OrCel |
Cambrex will provide manufacturing services for the product under a six-year deal (10/30) |
|
|||
Epitomics Inc.* |
Ventana Medical Systems Inc. (VMSI) |
Epitomics will create rabbit monoclonal antibodies for Ventana |
The antibodies are expected to be used in reagents for diagnostic applications; terms were not disclosed (11/18) |
|
|||
GenoMed Inc. (OTC BB:GMED) |
PhenoMed* (Malaysia) |
Agreement under which PhenoMed will market GenoMed's medical genomics services in the Asia-Pacific region |
The partnership is designed to expand GenoMed's ability to market services in the region (10/24) |
|
|||
NeoPharm Inc.* (NEOL) |
Avanti Polar Lipids Inc.* |
NeoPharm's cardiolipin-based transfection reagents, NeoPhectin and NeoPhectin-AT |
Avanti will market the line of products to its customers worldwide; terms were not disclosed (11/21) |
|
|||
Oxford Gene Technology* (UK) |
Amersham plc (USK: LSE:AHM) |
Agreement expanding the scope of Amersham's rights to OGT's DNA microarray patents |
Amersham gets rights to patents in sequence variation and analyzing poly- nucleotide sequences; Amersham also can sublicense the technology |
|
|||
Protein Polymer Technologies Inc. (OTC BB:PPTI) |
Spine Wave Inc.* |
Amendment of relationship calls for PPTI to supply product for clinical trials and prepare for commercial manufacturing |
The product is an injectable protein-based formulation for the repair of spinal discs; PPTI said it would receive about $1.2M under the revised deal (12/12) |
|
|||
Sirna Therapeutics Inc. (RNAI) |
Archemix Corp.* |
ARC183, an antithrombin aptamer |
Sirna will manufacture and supply the product for preclinical development through Phase IIa trials (10/27) |
|
|||
Transgenomic Inc. (TBIO) |
Intercell AG* (Austria) |
Contract for production of an Intercell immune-stimulating oligonucleotide that is a vaccine component |
Transgenomic will provide various services under the contract, including manufacture of preclinical material (11/18) |
|
|||
| | |||
Notes: | |||
# The information in the chart does not cover agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | |||
To read more on related topics, click on one of the words below.